FAST-Funded Communication Endpoint Leveraged for Prestigious FDA Grant

blog faq

FAST, the Foundation for Angelman Syndrome Therapeutics, is pleased to unveil an FDA Patient-Focused Drug Development Grant that will evaluate the expansion of the existing Observer-Reported Communication Ability (ORCA) measure for use with other rare neurodevelopmental disorders. The FAST-funded research team at Duke University was recently awarded the prestigious FDA Patient-Focused Drug Development Grant, designed […]

Angelman Syndrome Infrastructure Grant Update

Add a subheading

From Dr. David Segal, Dr. Jill Silverman, and Dr. Kyle Fink at UC Davis Having rebounded from the limiting conditions of COVID-19 restrictions, the Infrastructure Team is hard at work for the Angelman syndrome (AS) community. We have been busy building a lab that is devoted to Angelman syndrome research, establishing an infrastructure in which […]

Community statement from Ionis

IONIS UPDATE

 Dear Angelman Syndrome Community,  We are writing this letter to share with you an update on our progress towards initiating our clinical trial in people living with Angelman syndrome. Last year was incredibly difficult on so many levels, and while 2021 will continue to have its challenges, we remain hopeful that our lives will begin […]

Cas13 vs. Cas9: two different ways to potentially treat Angelman syndrome

segal lab

by Ulrika Beitnere, Segal Lab, UC Davis There is a new kind of CRISPR nuclease on the gene technology block called Cas13. What is so special about it and what is the main difference between the better-known Cas9? This is a question not only many parents have been asking, but also scientists! You might want […]

Further Understanding the FAST & GeneTx Relationship

fastxgenetx12

We have noticed a number of questions concerning how GeneTx is funded and specifically who pays for the salaries of the GeneTx employees.  We understand your concerns and would like to clear things up. In a nutshell, GeneTx is a separate company.  While FAST owns a majority of GeneTx, the company has other investors as […]

INSYNC-AS: A collaboration between FAST and the Simons Foundation Autism Research Initiative (SFARI)

Picture1 2048x417 1

INSYNC-AS: A collaboration between FAST and the Simons Foundation Autism Research Initiative (SFARI) The Foundation for Angelman Syndrome Therapeutics (FAST) is here to demonstrate our commitment to identifying and furthering scientific advancements for various potential therapeutics that treat Angelman syndrome (AS) through this exciting collaboration with the Simons Foundation Autism Research Initiative (SFARI). The launch […]

FAST Spain: The Dream Team

FAST España wrist bands

“Mom, don’t worry, I have come with a syndrome and the cure. It is on this path that I want you to be at my side.” Casilda Cebrián awoke in the middle of the night realizing it had been a dream. She was at the NICU next to her eight month old son, Anton, whom […]

Welcome FAST Latin America PART 1: FAST Argentina and FAST Colombia

FAST Argentina & FAST Colombia at Gala

Welcome FAST Latin America PART 1: FAST Argentina and FAST Colombia About 1 in 15,000-20,000 individuals have Angelman syndrome (AS). Latin America is home to 652 million people. That means there are about 42,000 people living with AS throughout Latin America. According to FAST Latin America (LatAm) there are, in fact, only about 1,600 families […]